Candida News and Research

RSS

Oral garlic does not reduce vaginal thrush, study finds

In a world-first study, led by the University of Melbourne and the Royal Women’s Hospital, researchers have found garlic does not significantly reduce vaginal candida (thrush).

17 Dec 2013

IBN and IBM discover new medical application for converted PET bottles

Researchers at Singapore's Institute of Bioengineering and Nanotechnology (IBN) and California's IBM Research - Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles.

10 Dec 2013

New material effective in destroying drug-resistant fungi

Researchers at Singapore’s Institute of Bioengineering and Nanotechnology (IBN) and California’s IBM Research – Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles.

9 Dec 2013

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis.

4 Dec 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Concordia University professors use funds to fight fungus and update aircraft

Thanks to new funding from the Government of Canada, two Concordia University professors just might create a greener aerospace industry and help cure fungal infections.

16 Nov 2013

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

Candida albicans is one of the leading causes of hospital-acquired infections in immune compromised patients. The risk of both developing candidiasis and the clinical outcome of infection is variable among patients, and the host-dependent factors that contribute to patient susceptibility to C. albicans infection are poorly understood.

4 Nov 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

Study shows how deadly Candida albicans might be rendered harmless

Candida albicans is a double agent: In most of us, it lives peacefully, but for people whose immune systems are compromised by HIV or other severe illnesses, it is frequently deadly. Now a new study from Johns Hopkins and Harvard Medical School shows how targeting a specific fungal component might turn the fungus from a lion back into a kitten.

25 Sep 2013

Microbiologist finds breakthrough herbal medicine treatment for common human fungal pathogen

A Kansas State University microbiologist has found a breakthrough herbal medicine treatment for a common human fungal pathogen that lives in almost 80 percent of people.

13 Sep 2013

New antibody could prevent Candida infections in patients who receive central lines

A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.

12 Sep 2013

Antioxidant substances in red wine, dark chocolate, olive oil linked with health benefits

The scientific spotlight focuses today on the healthful antioxidant substances in red wine, dark chocolate, olive oil, coffee, tea, and other foods and dietary supplements that are enticing millions of consumers with the promise of a healthier, longer life.

12 Sep 2013

Research shows how mucosal surfaces in body respond to C. albicans to prevent damage

Candida albicans is a common fungus found living in, and on, many parts of the human body. Usually this species causes no harm to humans unless it can breach the body's immune defences, where can lead to serious illness or death.

3 Sep 2013

FDA approves first mass spectrometer system in U.S. for identification of bacteria, yeasts

The U.S. Food and Drug Administration today allowed marketing in the U.S. of the first mass spectrometer system for automated identification of bacteria and yeasts that are known to cause serious illness in humans.

22 Aug 2013

Study shows ART has reduced immunosuppression and viremia among PHIV youth

The advent of antiretroviral therapy (ART) has transformed HIV from a death sentence into a chronic disease. In one of the largest studies of perinatally infected HIV (PHIV) patients to date, Agwu, et al, found that the proportion of patients on ART has increased and rates of viremia and advanced immunosuppression have decreased. But the rates of both markers in older patients are higher, according to an article in the Fall issue of The Journal of the Pediatric Infectious Diseases Society (JPIDS).

20 Aug 2013

Chemical compound prevents fungal cells from adhering to surfaces

Targeting serious and sometimes deadly fungal infections, a team of researchers at Worcester Polytechnic Institute (WPI) and the University of Massachusetts Medical School (UMMS) has discovered a chemical compound that prevents fungal cells from adhering to surfaces, which, typically, is the first step of the infection process used by the human pathogen Candida albicans (C. albicans).

14 Aug 2013

Newly developed palm-sized microarray platform could enable faster, more efficient drug discovery

A new palm-sized microarray that holds 1,200 individual cultures of fungi or bacteria could enable faster, more efficient drug discovery, according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.

25 Jun 2013

Common sugar molecule promising target for development of broad-spectrum vaccine

Developing new vaccines to protect against diseases that plague humans is fraught with numerous challenges-one being that microbes tend to vary how they look on the surface to avoid being identified and destroyed by the immune system. However, researchers from Brigham and Women's Hospital (BWH) have discovered a sugar polymer that is common on the cell surface of several pathogens.

28 May 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013